



Economic Evaluation of STA-Liatest D-Di for Exclusion of Venous thromboembolism (VTE) in ED for the US Healthcare System

Value Proposition

Improved patient outcomes and experience, shorter length of stay and cost reduction drive the recognition of value in today's rapidly-evolving and competitive healthcare environment. Stago contracted with Alira Health to conduct an economic evaluation comparing the use of the STA-Liatest D-Di assay in conjunction with a probability assessment model to other D-dimers.



Authors

Alira Health

Alira Health is an international advisory firm providing integrated strategy, execution and innovation services for healthcare and life science companies. Our strategists, bankers, doctors and scientists collaborate to fully understand every aspect of healthcare.

Our HEOR (Health Economics and Outcomes Research) expertise represented by our team of clinicians, health economists, and consultants work closely with regulatory, payer, and marketing experts to target economic and financial value.

At Alira Health, our HEOR studies focus on translating the clinical and technical benefits of a technology with economic evidence that keeps the entire healthcare system in perspective. We conduct health economics as defined in section 502(a) as “any analysis (including the clinical data, inputs, clinical or other assumptions, methods, results, and other components underlying or comprising the analysis) that identifies, measures, or describes the economic consequences, which may be based on the separate or aggregated clinical consequences of the represented health outcomes, of the use of a drug. Such analysis may be comparative to the use of another drug, to another health care intervention, or to no intervention.”

Alira Health's Approach to HEOR



Burden of Illness

HEOR generates evidence to prove clinical, economic and societal burden of diseases from multiple perspectives.



Economic Evaluation

HEOR develops real world health economic models backed by sound clinical evidence.



Clinical Pathway Validation

HEOR determines how changes in treatment can influence clinical scenarios and determine patient outcomes.



Health Economic and Economic Research (HEOR)

HEOR develops patient focused health economic studies, which establishes clinical and economic evidence for the given clinical conditions and indirect and mixed treatments.

Overview on Stago

With a staff close to 2,600 and the most advanced technologies, Stago formulates, manufactures and markets the broadest range of reagents and analytical instruments in Haemostasis, worldwide. Stago devotes its research and innovative skills to the development of increasingly effective medical diagnostic products and instrumentation.

Stago Group has acquired its expertise over many years, accompanying, and often leading, the rapid growth of this Haematology-related scientific discipline – Haemostasis. Today, Stago is the only independent international group in the *in vitro* diagnostics industry dedicated to Haemostasis and Thrombosis exploration.

See section 502(a), as amended by section 114 of FDAMA and section 3037 of the 21st Century Cures Act. As used in this guidance, the term “section 502(a)” refers to the part of that section specific to HCEI

This document contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country.



TABLE OF CONTENTS

Introduction	6
<hr/>	
Methodology	7
<hr/>	
Economic Evaluation of STA-Liatest D-Di for Exclusion of Venous thromboembolism (VTE)	8
<hr/>	
Value Proposition of STA-Liatest D-Di	11
<hr/>	
References	16
<hr/>	

INTRODUCTION

WHAT IS VENOUS THROMBOEMBOLISM?

Venous thromboembolism (VTE), which consists of deep vein thrombosis (DVT), a blood clot in a deep vein in the body, and pulmonary embolism (PE), the dislodgement of the clot and its passage into the lungs, is an important public health concern causing considerable morbidity and mortality.

Studies estimate that 10%–30% of all patients suffer mortality within 30 days; most deaths occur among those with PE, as an estimated 20%–25% of all PE cases present as sudden death [2]. Other serious complications of VTE include increased risk of recurrent thromboembolism and chronic morbidity (e.g., venous insufficiency, pulmonary hypertension).

INCIDENCE AND DIAGNOSIS

The overall annual incidence of VTE in the U.S. is estimated to be between 1 and 2 per 1000 people, or 300,000–600,000 cases [1,2,3]. About two thirds of patients with VTE present for care with DVT, and the remaining one third present with PE. In the US, approximately 50% to 70% of VTE patients are diagnosed in the Emergency Department (ED) of which, 60% have DVT and 40% have PE.

Stago Group conducted an international, multicenter, prospective nonrandomized, noninterventional clinical outcome management study, following the Clinical and Laboratory Standard Institute guideline (CLSI H59-A "Quantitative D-Dimer for the exclusion of venous thromboembolic disease; approved guideline). The study established a negative predictive value (NPV), sensitivity and specificity of 100%, 100% and 55.2% for DVT exclusion and 99.7%, 97.0% and 75.5% for PE exclusion, respectively [2, 64].

VTE COST TO HEALTHCARE IN THE US

Although data are lacking on the exact cost attributed to VTE, a recent analysis of healthcare claims estimated that the total annual healthcare cost for VTE ranges from \$7594 to \$16,644 per patient. With estimates of 300,000–600,000 incident cases per year, the cost equates to a yearly total of \$2 billion to \$10 billion attributable to VTE [7].

STA-LIATEST D-DI ASSAY

STA-Liatest D-Di assay demonstrates excellent performance when used in combination with a clinical score in relevant patients and has the potential to minimize the economic healthcare burden avoiding unnecessary and expensive imaging tests, improving patient experience through a faster diagnosis, decreasing complications and reducing overcrowding of EDs [2, 47].


HEALTH ECONOMICS

We conducted a **health economic analysis**, comparing the use of **STA-Liatest D-Di assay** for **the exclusion of VTE in patients with low/moderate pre-test probability (PTP)**, as defined in 2018 **ASH guideline** [24], with current **standard-of-care** and other FDA approved D-dimer assays for similar indications.

METHODOLOGY


SYSTEMATIC REVIEW

We conducted a systematic review of the literature by searching PubMed, Scopus, Ovid, and MEDLINE databases from January 2000 to December 2018 for studies comparing diagnostic costs, treatments, clinical pathways, outcomes, and hospitalization burden associated with management of VTE patients presented to ED in the US. The following types of studies were included: 1) prospective, randomized controlled trials that included VTE patients; 2) systematic reviews, including meta-analyses, focused on the diagnosis, treatment and outcomes of VTE patients; 3) studies evaluating burden of hospitalizations, ED overcrowding, morbidity and mortality associated costs; and 4) studies examining health care models to evaluate financial impacts of evolving guidelines for VTE diagnosis.



ECONOMIC EVALUATION

The economic evaluation was performed according to the definition of Health Care Economic Information (HCEI) as defined in section 502(a), as amended by section 114 of FDAMA and section 3037 of the 21st Century Cures Act.




ECONOMIC EVALUATION OF STA-LIATEST D-DI FOR EXCLUSION OF VTE

CLINICAL PATHWAY

Guidelines for management of venous thromboembolism such as American Society of Hematology 2018 guidelines [24] concluded that for patients at low (unlikely) VTE risk, using D-dimer as the initial test reduces the need for diagnostic imaging. For patients at high (likely) VTE risk, imaging is warranted¹. For PE diagnosis, ventilation perfusion scanning and computed tomography pulmonary angiography are the most validated tests, whereas lower or upper extremity DVT diagnosis uses ultrasonography. The economic impact of using STA-Liatest D-Di assay for the exclusion of VTE in patients with low/moderate clinical probability (DiET Study NCT01221805) has been compared with imaging alone for DVT and imaging and D-dimer simultaneously for PE for outpatients suspected of PE or DVT .

DiET Study NCT01221805



Note: ¹In the case of PE, D-Di for intermediate PTP patients is recommended if results can be obtained in a timely manner.

ECONOMIC EVALUATION OF STA-LIATEST D-DI FOR EXCLUSION OF DVT

HEALTH ECONOMIC ANALYSIS (DVT)

STA-LIATEST D-DI ASSAY AS in DiET Study NCT01221805 VS STANDARD OF CARE (IMAGING)

Care Pathway N°1 – Imaging only




Vs.

Care Pathway N°2 – Imaging + DD



Average savings per patient of Stago (care pathway N°2) vs. imaging only (care pathway N°1), on a basis of 100 patients presented to the ED with DVT prevalence of 22.1%, savings categorized into diagnosis, treatment and workflow related.



STA-LIATEST D-DI ASSAY AS in DiET Study NCT01221805 VS COMPETITORS

Care Pathway N°2 – Imaging + DD- Stago




Vs.

Care Pathway N°2 – Imaging + DD- Competitors



Average savings per patient of Stago (care pathway N°2) vs. competitors (care pathway N°2), on a basis of 100 patients presented to the ED with DVT prevalence of 22.1%, savings categorized into diagnosis, treatment and workflow related.



Average savings split by competitors



Vs.



PTP



Imaging



D-dimer

+ Test Combinations

ECONOMIC EVALUATION OF STA-LIATEST D-DI FOR EXCLUSION OF PE

HEALTH ECONOMIC ANALYSIS (PE)

STA-LIATEST D-DI ASSAY AS RECOMMENDED IN DiET Study NCT01221805 VS STANDARD OF CARE

Care Pathway N°2 – Imaging+DD simultaneously




Vs.

Care Pathway N°3 – 2018 ASH



Average savings per patient of Stago (care pathway N°2) vs. imaging and D-dimer in parallel (care pathway N°1), on a basis of 100 patients presented to the ED with PE prevalence of 7%, savings categorized into diagnosis, treatment and workflow related.



Overall savings per patient are \$1,233 when introducing the Stago DD test into the diagnosis algorithm vs. imaging only.

STA-LIATEST D-DI ASSAY AS in DiET Study NCT01221805 VS COMPETITORS

Care Pathway N°3 – Imaging + DD- Stago




Vs.

Care Pathway N°3 – Imaging + DD- Competitors



Average savings per patient of Stago (care pathway N°3) vs. competitors (care pathway N°3), on a basis of 100 patients presented to the ED with PE prevalence of 7%, savings categorized into diagnosis, treatment and workflow related.



Overall Stago's average savings are \$772 per patient vs. studied competitors

Average savings split by competitors



Vs.



+ Test Combinations

VALUE PROPOSITION OF STA-LIATEST D-DI

GENERAL VALUE PROPOSITION

Health care reimbursement models are transitioning from volume-based to value-based models. Value-based models focus on patient outcomes both during the hospital admission and post discharge. These models place emphasis on cost, quality of care, and coordination of multidisciplinary services and continuum of care.

Overall imaging savings to the US healthcare system is ~ \$620M a year for VTE patients categorized in low / moderate clinical probability, as ~820,000 patients can safely be ruled out with STA-Liatest D-Di test avoiding unnecessary imaging if the diagnostic triage as presented in DiET Study NCT01221805 is followed.

With no differences in diagnostic efficacy, the diagnostic triage presented in DiET Study NCT01221805 may be considered a dominant strategy, i.e. giving the same result at a lower cost.



Reduced delay and overcrowding in the ED.



Improved patient experience through a **faster diagnosis / decreased risk of complications.**




Avoided unnecessary imaging associated with a small but significant **risk of complications.**



Validated by **FDA for exclusion** of VTE in patients with low to moderate risk as per CLSI H59-A guidelines.



STA-Liatest D-Di



VALUE PROPOSITION OF STA-LIATEST D-DI

VALUE PROPOSITION- PATIENT

820.000 VTE patients with low/mod PTP can **safely be ruled out** annually with Stago's D-dimer test and **avoiding imaging and its related diagnosis complications.**



Improved patient experience through a **faster diagnosis**



Avoided unnecessary imaging associated with a small but significant **risk of complications**, among low probability patients



Avoided unnecessary waiting time in the Emergency Department

Savings related to **avoiding complications** by introduction of Stago's D-dimer test in the diagnosis pathway for **VTE**



~\$770/ VTE patient



~\$382/ VTE patient



~\$512/ VTE patient



~\$412/ VTE patient



~\$363/ VTE patient



In a multi-center international clinical study conducted according to CLSI H59-A guideline at multiple sites in the United States, Europe and Canada, STA-Liatest D-Di has demonstrated its ability to safely exclude DVT in conjunction with a clinical pretest probability assessment in more than 2000 outpatients with low to moderate risk of VTE.

VALUE PROPOSITION OF STA-LIATEST D-DI

VALUE PROPOSITION – HEALTHCARE PROFESSIONALS

\$76M annual savings of **HCP costs**, linked to the number of low/mod PTP VTE patients safely ruled out with DD and avoided imaging



Reduced number of ultrasounds decreasing physician related costs



Increased physician availability

Savings related to HCP costs in the United States



~\$76M
year savings



~\$38M
year savings



~\$51M
year savings



~\$42M
year savings



~\$38M
year savings






In a multi-center international clinical study conducted according to CLSI H59-A guideline at multiple sites in the United States, Europe and Canada, STA-Liatest D-Di has demonstrated its ability to safely exclude DVT in conjunction with a clinical pretest probability assessment in more than 2000 outpatients with low to moderate risk of VTE.

VALUE PROPOSITION OF STA-LIATEST D-DI

VALUE PROPOSITION – HEALTHCARE PROVIDERS

\$82M savings of ED costs per year, linked to better diagnostic management of low/mod PTP patients*

-  Reduced delay and overcrowding in the ED
-  Reduced number of ultrasounds decreasing physician related costs
-  Increased physician availability

Savings related to introduction of Stago's D-dimer test in the diagnosis pathway for **VTE**

 **~\$82M year savings**

 **~\$11M year savings**

 **~\$55M year savings**

 **~\$22M year savings**


 **~\$20M year savings**



In a multi-center international clinical study conducted according to CLSI H59-A guideline at multiple sites in the United States, Europe and Canada, STA-Liatest D-Di has demonstrated its ability to safely exclude DVT in conjunction with a clinical pretest probability assessment in more than 2000 outpatients with low to moderate risk of VTE.

ECONOMIC EVALUATION OF STA-LIATEST D-DI FOR EXCLUSION OF VTE

SAVINGS FOR THE HEALTHCARE SYSTEM



Note: *The savings were calculated using the pathway described DiET Study NCT01221805.

REFERENCES

1. Aguilar et al, Blood Coagulation and Fibrinolysis (2018).
2. Beckman et al., American Journal of Prevention Medicine, Venous Thromboembolism A Public Health Concern (2010)
3. Běloháve et al. Clinical Cardiology Review, Pulmonary embolism (2013)
4. Bevis, Deep vein thrombosis, Elsevier Ltd (2016)
5. Broen, Predicting the need for further thrombosis diagnostics in suspected DVT is increased by using age adjusted D-dimer values, Thrombosis Research 145, 107–108 (2016)
6. Cate-Hoek, Cost-effectiveness of ruling out deep venous thrombosis in primary care versus care as usual, Journal of Thrombosis and Haemostasis, 7: 2042–2049 (2009).
7. CDC, Center for Disease Control and Prevention, National Hospital Ambulatory Medical Care Survey: 2015 Emergency Department Summar (2015)
8. CDC, Center for Disease Control and Prevention, Venous Thromboembolism (Blood Clots), Data & Statistics (2018)
9. Coche, Using Dual-Detector Helical CT Angiography to Detect Deep Venous Thrombosis in Patients with Suspicion of Pulmonary Embolism Diagnostic Value and Additional Findings, American Journal of Roentgenology; 176: 1035-1039 (2001)
10. Cooper, Evaluating the Cost-Effectiveness of Diagnostic Tests in Combination: Is It Important to Allow for Performance Dependency? Value in health 16, 536–541 (2013)
11. Constans, Comparison of Four Clinical Prediction Scores for the Diagnosis of Lower Limb Deep Venous Thrombosis in Outpatients, Am J Med.; 115: 436–440 (2003)
12. CPT DD: Clinical Diagnostic Laboratory Fee Schedule. (2018)
13. Dasta, Daily Hospitalization Costs in Patients with Deep Vein Thrombosis or Pulmonary Embolism Treated with Anticoagulant Therapy, Thrombosis Research 135, 303–310 (2015)
14. Dunn, Anaphylaxis: A Payor's Perspective on Epinephrine Autoinjectors, The American Journal of Medicine, 127, S45-S50 (2014)
15. Duriseti, Value of Quantitative D-dimer Assays in Identifying Pulmonary Embolism: Implications from a Sequential Decision Model, Academic Emergency Medicine; 13:755–766 (2006)
16. Duwe, Evaluation of the Lower Extremity Veins in Patients with Suspected Pulmonary Embolism - A Retrospective Comparison of Helical CT Venography, and Sonography, American Journal of Roentgenology; 175: 1525-1531 (2000)
17. ED Coding, Vascular Payment Information (2017)
18. ED H. Charges 1: Faxton St. Luke's Healthcare Hospital Patient Pricing Information (2018)
19. ED H. Charges 2: The Bellevue Hospital Patient Pricing (2018)
20. ED H. Charges 3: Maine Coast Memorial Hospital, Physician Services - Price Listing (2018)
21. ED H. Charges 4: Lourdes Ascension, Patient Guide (2018)
22. Fanikos, Hospital Costs of Acute Pulmonary Embolism, 126:127-32 (2013)
23. Farm, Age-adjusted D-dimer cut-off leads to more efficient diagnosis of venous thromboembolism in the emergency department: a comparison of four assays, J Thromb Haemost; 16: 866–75 (2018)
24. FDA 510k Hemos IL: K073042
25. FDA 510k Innovance®: K161312
26. FDA 510k Tina-quant: K062203
27. FDA 510k Vidas: K040882
28. Fuentes Camps, Cost-effectiveness of the deep vein thrombosis diagnosis process in primary care, Aten Primaria;48(4):251---257 (2016)
29. Garg, Thromboembolic Disease Comparison of Combined CT Pulmonary Angiography and Venography with Bilateral Leg Sonography in 70 Patients, American Journal of Roentgenology; 175: 997-1001 (2001)
30. Goodacre, Measurement of the clinical and cost-effectiveness of non-invasive diagnostic testing strategies for deep vein thrombosis, Health Technology Assessment; Vol. 10: No. 15 (2006)
31. Harper, D-dimer concentration increases with age reducing the clinical value of the D-dimer assay in the elderly, Internal Medicine Journal 37, 607–613 (2007)

19. Karami Djurabi, Comparison of the clinical usefulness of two quantitative D-Dimer tests in patients with a low clinical probability of Pulmonary Embolism, *Thrombosis Research* 123, 771–774 (2009)
20. Kilroy, Emergency department investigation of deep vein thrombosis, *Emerg Med J*; 20:29–32 (2003)
21. Kim, Anaphylaxis to Iodinated Contrast Media: Clinical Characteristics Related with Development of Anaphylactic Shock, *PLoS ONE* 9(6): e100154 (2014)
22. Kline, Diagnosis and Exclusion of Pulmonary Embolism, *Thrombosis Research*, (2017)
23. Kooiman, Incidence and predictors of contrast-induced nephropathy following CT-angiography for clinically suspected acute pulmonary embolism, *International Society on Thrombosis and Haemostasis* (2010)
24. Lim, American Society of Hematology guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism, (2018)
25. McQueen, Ultrasonography for suspected deep vein thrombosis: how useful is single-point augmentation?, *Clinical Radiology* 64, 148e155 (2009)
26. Miron, Clinical assessment of suspected deep vein thrombosis: comparison between a score and empirical assessment, *Journal of Internal Medicine*; 247: 249-254 (2000)
38. Mouawad, Elimination of medically unnecessary duplex venous scanning based on an established algorithm can result in significant cost savings under Medicare for the institution and the taxpayer, *Journal of vascular surgery: venous and lymphatic disorder*, Volume 3, Number 1, (2014)
39. Mousa, Appropriate Use of D-Dimer Testing Can Minimize Over-Utilization of Venous Duplex Ultrasound in a Contemporary High-Volume Hospital, *Ann Vasc Surgery*; 29(2): 311–317 (2015)
40. Mitchell, Contrast nephropathy following computed tomography angiography of the chest for pulmonary embolism in the emergency department, *Journal of Thrombosis and Haemostasis*, 5: 50–54 (2007)
41. Mitchell, Prospective Study of the Incidence of Contrast-induced Nephropathy Among Patients Evaluated for Pulmonary Embolism by Contrast-enhanced Computed Tomography, *Academic emergency medicine*; 19: 618–625 (2012)
42. NCGC, Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing Venous thromboembolic diseases, *Clinical Guideline, Appendices A-M* (2012)
43. Neale, Evaluation of the Simplify D-dimer assay as a screening test for the diagnosis of deep vein thrombosis in an emergency department, *Emerg Med J* 2004;21:663–666 (2004)
44. Norlin, A Cost-effectiveness Analysis of Diagnostic Algorithms of Deep Vein Thrombosis at the Emergency Department, *Thrombosis Research* 126, 195–199 (2010)
45. NPs Services Fees: American College of Emergency Physicians, Medicare Mid-Level Provider FAQ
46. Olaf, Deep Venous Thrombosis, *Emerg Med Clin N Am* 35, 743–770 (2018)
47. Pernod et al, Validation of STA-Liatest D-Di assay for exclusion of pulmonary embolism according to the latest Clinical and Laboratory Standard Institute/Food and Drug Administration guideline. Results of a multicenter management study (2017)
48. Peterson, Computed tomographic venography is specific but not sensitive for diagnosis of acute lower extremity deep venous thrombosis in patients with suspected pulmonary embolus, *Journal of vascular surgery*, Volume 34, Number 5 (2001)
49. Qun Luo, Prevalence of Venous Thromboembolic Events and Diagnostic Performance of the Wells Score and Revised Geneva Scores for Pulmonary Embolism in Patients with Interstitial Lung Disease: A Prospective Study, *Heart, Lung and Circulation*, 23:778-785, (2014)
50. Riva, Age-adjusted D-dimer to rule out deep vein thrombosis: findings from the Palladio algorithm, *Journal of Thrombosis and Haemostasis*, 16: 271–278 (2018)
51. Schreyer, The Economics of an Admissions Holding Unit, *Western Journal of Emergency Medicine*, Volume 18, no. 4 (2017)
52. Segal, Review of the Evidence on Diagnosis of Deep Venous Thrombosis and Pulmonary Embolism, *Ann Farm Med*, 5:63-73, (2007)
53. Soo Hoo, Does a Clinical Decision Rule Using d-Dimer Level Improve the Yield of Pulmonary CT Angiography?, *Cardiopulmonary Imaging*, 196:1059-1064, (2011)
54. Stone, Deep vein thrombosis: pathogenesis, diagnosis, and medical management, *Cardiovasc Diagn Ther*; 7 (Suppl 3): S276-S284 (2017)
55. Singh, Pulmonary embolism rule-out criteria (PERC) in pulmonary embolism—revisited: A systematic review and meta-analysis, *Em Med J*, 0:701–706, (2012)
56. Theodoro, Real-Time B-Mode Ultrasound in the ED Saves Time in the Diagnosis of Deep Vein Thrombosis, *American Journal of Emergency Medicine*, Volume 22, Number 3 (2004)
57. Theodorou, Sonography and venography of the lower extremities for diagnosing deep vein thrombosis in symptomatic patients, *Journal of Clinical Imaging* 27, 180– 183 (2003)
58. Theodoro, Real-Time B-Mode Ultrasound in the ED Saves Time in the Diagnosis of Deep Vein Thrombosis, *American Journal of Emergency Medicine*, Volume 22, Number 3 (2004)
59. Theodorou, Sonography and venography of the lower extremities for diagnosing deep vein thrombosis in symptomatic patients, *Journal of Clinical Imaging* 27, 180– 183 (2003)

56. Traub, Risk Factors for Radiocontrast Nephropathy After Emergency Department Contrast-enhanced Computerized Tomography, *Academic Emergency Medicine*; 20:40–45 (2013)
57. US Census, U.S. and World Population Clock (2018)
58. Venkatesh, Evaluation of Pulmonary Embolism in the Emergency Department and Consistency With a National Quality Measure: Quantifying the opportunity for improvement, *Arch Intern Med*, 172(13): 1028–1032, (2012)
59. Waheed, Deep Vein Thrombosis, M J StubbsStatPearls Publishing LLC (2018)
60. Wang, Imaging Trends in Acute Venous Thromboembolic Disease: 2000 to 2015, *American College of Radiology*, (2017)
61. Ward, Cost-effectiveness of Lower Extremity Compression Ultrasound in Emergency Department Patients With a High Risk of Hemodynamically Stable Pulmonary Embolism, *Society for Academic Emergency Medicine* (2010)
62. Woo, Ruling out low- and moderate-risk probability pulmonary emboli without radiological imaging: appraisal of a clinical prediction algorithm after implementation and revision with higher D-dimer thresholds, *Int Med J*, (2016)
63. Wysowski, Deaths Attributed to X-Ray Contrast Media on U.S. Death Certificates, *American Journal of Roentgenology*;186: 613-615Y (2006)
64. Yusuf et al. *Journal of Hospital Administration*, Emergency department visits by patients with venous thromboembolism, 1998-2009 (2012)

The content of this publication is for general information only. Alira Health limits the use of trademarks or logos to objectively identify the products, which are the subject of this publication. No reference made in this publication to any specific trademark or logo implies and/or constitute any endorsement, association or recommendation to use the designated product.

